Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)- phosphonylmethoxyethyl]adenine) in HIV-infected patients

Journal of Infectious Diseases

Volumn 176, Issue 2, 1997, Pages 406-413

  Barditch Crovo, P ^a   Toole, J ^b   Hendrix, C W ^b   Cundy, K C ^b   Ebeling, D ^b   Jaffe, H S ^b   Lietman, P S ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPHILICITY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRUCTURE ANALYSIS; VIRUS INHIBITION;

EID: 0030842430     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514057     Document Type: Article

References (14)

1. DeClercq E. Broad spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkyl purines and pyrimidines. Biochem Pharmacol 1991;42:963-72.
2. Tsai CC, Follis KE, Sabo A, et al. Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J Infect Dis 1994;169:260-6.
3. Castro LM, Kern ER, DeClercq E, et al. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res 1991;16:101-14.
4. Balzarini J, Naesens L, Herdewun P, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989;86:332-6.
5. Heijtink RA, DeWilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993;21:141-53.
6. Reymen D, Naesens L, Balzarini, Holy A, DeClercq E. Antiviral activity of selected nucleoside analogues against human herpes virus type 6. Nucleosides Nucleotides 1995;14:567-70.
7. Naesens L, Balzarini J, DeClercq E. Therapeutic potential of PMEA as an antiviral drug. Rev Med Virol 1994;4:147-59.
8. Baizarini J, Naesens L, Slachmuylders, et al. 9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 1991;5:21-8.
9. Balzarini J, Hao Z, Herdewijn D, Johns DG, DeClercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV compound. Proc Natl Acad Sci USA 1991;88:1499-503.
10. Collier AC, Coombs RW, Nienow J, et al. A phase I/II study of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in advanced HIV infection (abstract 563). In: 1st National Conference on Human Retroviruses and Related Infections: program and abstracts (Washington, DC). Washington, DC: American Society for Microbiology, 1994:32.
11. Walker RE, Vogel SE, Jaffe HS, et al. A phase I/II study of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in HIV-infected patients (abstract 522). In: 1st National Conference on Human Retroviruses and Related Infections: program and abstracts (Washington, DC). Washington DC: American Society for Microbiology, 1994:28.
12. Cundy KC, Barditch-Crovo P, Walker RE, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type-1 infected patients. Antimicrob Agents Chemother 1995;39:2401-5.
13. Cundy KC, Shaw JP, Lee WA. Oral, subcutaneous, and intramuscular bioavailability of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl)adenine in cynomolgus monkeys. Antimicrob Agents Chemother 1994;38:365-8.
14. Palu G, Stefanelli S, Rassu M, Parolin C, Balzarini J, DeClercq E. Cellular uptake of phosphonylmethoxyalkyl derivatives. Antiviral Res 1991;16:115-9.